

12 January 2026

cyclopharm



cyclomedica
technegas

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

Lucile Packard Children's Hospital Stanford to Implement Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce that it has entered into an agreement with Stanford Medicine Children's Health to implement Technegas® at Lucile Packard Children's Hospital Stanford. This marks the first dedicated children's hospital in the United States to adopt Technegas, representing an important milestone in the early stages of the U.S. commercial rollout.

Technegas' established safety profile, ease of use, patient compliance, low radiation dose, and expanding clinical utility beyond pulmonary embolism make it an excellent imaging agent for paediatric patients, where minimising radiation exposure is essential and high-quality functional lung imaging is vital.

Cyclopharm Managing Director James McBrayer said: "We are delighted that Lucile Packard Children's Hospital Stanford will be the first dedicated children's hospital in the U.S. to adopt Technegas. Stanford Medicine was among the earliest major U.S. centres to introduce Technegas for adult patients. We look forward to supporting Stanford Medicine Children's Health as they integrate Technegas into their practice."

Cyclopharm continues to progress a growing number of U.S. installations across leading academic and clinical centres as the Company advances its strategy to broaden access to Technegas for patients nationwide.

ENDS

This ASX announcement was authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX-listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas used in functional lung ventilation imaging.

Technegas

Technegas technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro-furnaced for a few seconds at around 2,700 °C. The resultant gas-like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas, together with advancements in complementary technology, multimodality imaging, and analytical software, is being utilised in other disease states, including COPD, asthma, pulmonary hypertension, and certain interventional applications, such as lobectomies in lung cancer and lung volume reduction surgery.